Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) (INSPIRE)
Discontinuation of Disease-Modifying Treatment for Multiple Sclerosis
US court permits generic version of Teva MS drug a year sooner
Immunology 2014
Regional Susceptibility to TNF-α Induction of Murine Brain Inflammation via Classical IKK/NF-κB Signalling.
Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound effect and similitude.
A genome-wide association study of brain lesion distribution in multiple sclerosis.
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year.
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis.
Receptos to deliver scientific presentations about RPC1063 at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Company restores access to multiple sclerosis drug after pressure from neurologists.
ALSUntangled No. 8: Low dose naltrexone for ALS.
Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
Treatment of neuromyelitis optica.
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.
Treatment of acute transverse myelitis and its early complications.
IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis.
The Stigma Scale for Chronic Illnesses 8-Item Version (SSCI-8): Development, Validation and Use Across Neurological Conditions.
Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS.
Good Early Results for HERV Suppressor in MS
New approaches in the management of multiple sclerosis.
Assessment of statistical significance and clinical relevance.
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.

Pages